Loading
Latest filing published 31 Jul 2017 for Helix BioPharma Corp., €3,079.
Marek Jan Orlowski is a declared insider of Helix BioPharma Corp., with filings sourced from SEDI. Between 25 July 2017 and 26 July 2017, the trades on record add up to 2 filings.
Every open-market trade on record is a sale: 2 sales worth €23k.
The latest filing, published on 31 July 2017, reports an open-market sale of €3,079 in Helix BioPharma Corp. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations